Chera BS, Sheth SH, Patel SA, et al. - The recommended phase 2 dose of adavosertib for head and neck squamous cell carcinoma (HNSCC) is 100 mg (twice daily on Monday, Tuesday, and Wednesday of weeks 1, 2, 4, 5, 7, and 8), given in combination with 70 grays (Gy) of intensity-modulated radiotherapy and cisplatin 30 mg/m ² .

• This phase 1b trial involved 12 patients with intermediate-risk/high-risk HNSCC.

• All patients received an 8-week course of concurrent intensity-modulated radiotherapy at 70 Gy, cisplatin 30 mg/m ² weekly, and adavosertib (twice daily on Monday, Tuesday, and Wednesday of weeks 1, 2, 4, 5, 7, and 8).

• Adavosertib (AZD1775) is an inhibitor of the Wee1 kinase.

• A dose-limiting toxicity occurred in three patients (25%), and adavosertib 150 mg resulted in two dose-limiting toxicities.

• The 12-week posttreatment objective response rate was 100%.

• 1-year progression-free and overall survival rates were both estimated to be 90%.

• At 100 mg, adavosertib was most tolerable.